Loading…

Densiron-68 heavy silicone oil in cases of PVR. Anatomic and functional outcomes

To evaluate the safety and efficacy of Densiron-68 heavy silicone oil in the clinical management of complex retinal detachments with proliferative vitreoretinopathy (PVR). We present a prospective, interventional noncomparative case series of 80 eyes of 79 consecutive patients. The primary end point...

Full description

Saved in:
Bibliographic Details
Published in:Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2009-04, Vol.106 (4), p.320-326
Main Authors: Stappler, T, Heimann, H, Gibran, S K, Groenewald, C, Pearce, I A, Wong, D
Format: Article
Language:ger
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 326
container_issue 4
container_start_page 320
container_title Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
container_volume 106
creator Stappler, T
Heimann, H
Gibran, S K
Groenewald, C
Pearce, I A
Wong, D
description To evaluate the safety and efficacy of Densiron-68 heavy silicone oil in the clinical management of complex retinal detachments with proliferative vitreoretinopathy (PVR). We present a prospective, interventional noncomparative case series of 80 eyes of 79 consecutive patients. The primary end point was anatomical reattachment of the retina, defined as retinal reattachment in the absence of any tamponade agent. The secondary end point was to record the visual function and surgical complications. Inclusion criteria were PVR stages B-CA4, including posterior or inferior retinal breaks and the patient's inability to posture. Patients were 59.1 (+/-18.1) years old, male:female =48:32, R:L=40:40. Fifty-six patients (70%) had previous unsuccessful retinal surgery, and 24 (30%) received heavy silicone oil at their first procedure. The extent of the detachments was 2.46 quadrants (+/-0.83) with macular involvement in 49 cases (61%). Fifty-six (67.5%) patients achieved retinal reattachment with one retinal operation and no tamponade, 64 (80%) achieved retinal reattachment with more than one operation and no tamponade, and 72 (90%) achieved a flat retina with tamponade in situ. Visual acuity rose from 1.48 LogMar (+/-0.91) to 1.12 (+/-0.82; p=0.009). Densiron was removed after 126 days (+/-55.1). The treatment of PVR remains challenging. No tamponade agent can provide simultaneous support for the superior as well as the inferior retina; therefore, a tamponade agent that "sinks" is a welcome new tool for the surgeon. We regard the use of heavy as well as conventional silicone oil as complementary to each other.
doi_str_mv 10.1007/s00347-008-1798-8
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67151381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67151381</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-f985acac31729fb770b442c230030d9c000e836de81f664172e5dc7a28c391d93</originalsourceid><addsrcrecordid>eNo1kM1KAzEYRYMgtlYfwI1k5S41yTeTn2Wpv1CwiLod0sw3GJlJ6mRG6Ns7YF3dzeFy7iXkSvCl4FzfZs6h0Ixzw4S2hpkTMhcFAOOFhBk5z_mLc65KkGdkJowCJZWak-0dxhz6FJky9BPdz4Hm0AafItIUWhoi9S5jpqmh24_XJV1FN6QueOpiTZsx-iGk6FqaxsGnDvMFOW1cm_HymAvy_nD_tn5im5fH5_Vqw_YC7MAaa0rnnQehpW12WvNdUUgvYZrBa-snVzSgajSiUaqYKCxrr500HqyoLSzIzV_vvk_fI-ah6kL22LYuYhpzpbQoBRgxgddHcNx1WFf7PnSuP1T_H8Av5DBbAw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67151381</pqid></control><display><type>article</type><title>Densiron-68 heavy silicone oil in cases of PVR. Anatomic and functional outcomes</title><source>Alma/SFX Local Collection</source><creator>Stappler, T ; Heimann, H ; Gibran, S K ; Groenewald, C ; Pearce, I A ; Wong, D</creator><creatorcontrib>Stappler, T ; Heimann, H ; Gibran, S K ; Groenewald, C ; Pearce, I A ; Wong, D</creatorcontrib><description>To evaluate the safety and efficacy of Densiron-68 heavy silicone oil in the clinical management of complex retinal detachments with proliferative vitreoretinopathy (PVR). We present a prospective, interventional noncomparative case series of 80 eyes of 79 consecutive patients. The primary end point was anatomical reattachment of the retina, defined as retinal reattachment in the absence of any tamponade agent. The secondary end point was to record the visual function and surgical complications. Inclusion criteria were PVR stages B-CA4, including posterior or inferior retinal breaks and the patient's inability to posture. Patients were 59.1 (+/-18.1) years old, male:female =48:32, R:L=40:40. Fifty-six patients (70%) had previous unsuccessful retinal surgery, and 24 (30%) received heavy silicone oil at their first procedure. The extent of the detachments was 2.46 quadrants (+/-0.83) with macular involvement in 49 cases (61%). Fifty-six (67.5%) patients achieved retinal reattachment with one retinal operation and no tamponade, 64 (80%) achieved retinal reattachment with more than one operation and no tamponade, and 72 (90%) achieved a flat retina with tamponade in situ. Visual acuity rose from 1.48 LogMar (+/-0.91) to 1.12 (+/-0.82; p=0.009). Densiron was removed after 126 days (+/-55.1). The treatment of PVR remains challenging. No tamponade agent can provide simultaneous support for the superior as well as the inferior retina; therefore, a tamponade agent that "sinks" is a welcome new tool for the surgeon. We regard the use of heavy as well as conventional silicone oil as complementary to each other.</description><identifier>EISSN: 1433-0423</identifier><identifier>DOI: 10.1007/s00347-008-1798-8</identifier><identifier>PMID: 18636266</identifier><language>ger</language><publisher>Germany</publisher><subject>Female ; Humans ; Male ; Middle Aged ; Ophthalmic Solutions - administration &amp; dosage ; Recovery of Function - drug effects ; Silicone Oils - administration &amp; dosage ; Treatment Outcome ; Vision Disorders - diagnosis ; Vision Disorders - etiology ; Vision Disorders - prevention &amp; control ; Vitreoretinopathy, Proliferative - complications ; Vitreoretinopathy, Proliferative - drug therapy</subject><ispartof>Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2009-04, Vol.106 (4), p.320-326</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18636266$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stappler, T</creatorcontrib><creatorcontrib>Heimann, H</creatorcontrib><creatorcontrib>Gibran, S K</creatorcontrib><creatorcontrib>Groenewald, C</creatorcontrib><creatorcontrib>Pearce, I A</creatorcontrib><creatorcontrib>Wong, D</creatorcontrib><title>Densiron-68 heavy silicone oil in cases of PVR. Anatomic and functional outcomes</title><title>Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft</title><addtitle>Ophthalmologe</addtitle><description>To evaluate the safety and efficacy of Densiron-68 heavy silicone oil in the clinical management of complex retinal detachments with proliferative vitreoretinopathy (PVR). We present a prospective, interventional noncomparative case series of 80 eyes of 79 consecutive patients. The primary end point was anatomical reattachment of the retina, defined as retinal reattachment in the absence of any tamponade agent. The secondary end point was to record the visual function and surgical complications. Inclusion criteria were PVR stages B-CA4, including posterior or inferior retinal breaks and the patient's inability to posture. Patients were 59.1 (+/-18.1) years old, male:female =48:32, R:L=40:40. Fifty-six patients (70%) had previous unsuccessful retinal surgery, and 24 (30%) received heavy silicone oil at their first procedure. The extent of the detachments was 2.46 quadrants (+/-0.83) with macular involvement in 49 cases (61%). Fifty-six (67.5%) patients achieved retinal reattachment with one retinal operation and no tamponade, 64 (80%) achieved retinal reattachment with more than one operation and no tamponade, and 72 (90%) achieved a flat retina with tamponade in situ. Visual acuity rose from 1.48 LogMar (+/-0.91) to 1.12 (+/-0.82; p=0.009). Densiron was removed after 126 days (+/-55.1). The treatment of PVR remains challenging. No tamponade agent can provide simultaneous support for the superior as well as the inferior retina; therefore, a tamponade agent that "sinks" is a welcome new tool for the surgeon. We regard the use of heavy as well as conventional silicone oil as complementary to each other.</description><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ophthalmic Solutions - administration &amp; dosage</subject><subject>Recovery of Function - drug effects</subject><subject>Silicone Oils - administration &amp; dosage</subject><subject>Treatment Outcome</subject><subject>Vision Disorders - diagnosis</subject><subject>Vision Disorders - etiology</subject><subject>Vision Disorders - prevention &amp; control</subject><subject>Vitreoretinopathy, Proliferative - complications</subject><subject>Vitreoretinopathy, Proliferative - drug therapy</subject><issn>1433-0423</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNo1kM1KAzEYRYMgtlYfwI1k5S41yTeTn2Wpv1CwiLod0sw3GJlJ6mRG6Ns7YF3dzeFy7iXkSvCl4FzfZs6h0Ixzw4S2hpkTMhcFAOOFhBk5z_mLc65KkGdkJowCJZWak-0dxhz6FJky9BPdz4Hm0AafItIUWhoi9S5jpqmh24_XJV1FN6QueOpiTZsx-iGk6FqaxsGnDvMFOW1cm_HymAvy_nD_tn5im5fH5_Vqw_YC7MAaa0rnnQehpW12WvNdUUgvYZrBa-snVzSgajSiUaqYKCxrr500HqyoLSzIzV_vvk_fI-ah6kL22LYuYhpzpbQoBRgxgddHcNx1WFf7PnSuP1T_H8Av5DBbAw</recordid><startdate>200904</startdate><enddate>200904</enddate><creator>Stappler, T</creator><creator>Heimann, H</creator><creator>Gibran, S K</creator><creator>Groenewald, C</creator><creator>Pearce, I A</creator><creator>Wong, D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200904</creationdate><title>Densiron-68 heavy silicone oil in cases of PVR. Anatomic and functional outcomes</title><author>Stappler, T ; Heimann, H ; Gibran, S K ; Groenewald, C ; Pearce, I A ; Wong, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-f985acac31729fb770b442c230030d9c000e836de81f664172e5dc7a28c391d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>2009</creationdate><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ophthalmic Solutions - administration &amp; dosage</topic><topic>Recovery of Function - drug effects</topic><topic>Silicone Oils - administration &amp; dosage</topic><topic>Treatment Outcome</topic><topic>Vision Disorders - diagnosis</topic><topic>Vision Disorders - etiology</topic><topic>Vision Disorders - prevention &amp; control</topic><topic>Vitreoretinopathy, Proliferative - complications</topic><topic>Vitreoretinopathy, Proliferative - drug therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>Stappler, T</creatorcontrib><creatorcontrib>Heimann, H</creatorcontrib><creatorcontrib>Gibran, S K</creatorcontrib><creatorcontrib>Groenewald, C</creatorcontrib><creatorcontrib>Pearce, I A</creatorcontrib><creatorcontrib>Wong, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stappler, T</au><au>Heimann, H</au><au>Gibran, S K</au><au>Groenewald, C</au><au>Pearce, I A</au><au>Wong, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Densiron-68 heavy silicone oil in cases of PVR. Anatomic and functional outcomes</atitle><jtitle>Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft</jtitle><addtitle>Ophthalmologe</addtitle><date>2009-04</date><risdate>2009</risdate><volume>106</volume><issue>4</issue><spage>320</spage><epage>326</epage><pages>320-326</pages><eissn>1433-0423</eissn><abstract>To evaluate the safety and efficacy of Densiron-68 heavy silicone oil in the clinical management of complex retinal detachments with proliferative vitreoretinopathy (PVR). We present a prospective, interventional noncomparative case series of 80 eyes of 79 consecutive patients. The primary end point was anatomical reattachment of the retina, defined as retinal reattachment in the absence of any tamponade agent. The secondary end point was to record the visual function and surgical complications. Inclusion criteria were PVR stages B-CA4, including posterior or inferior retinal breaks and the patient's inability to posture. Patients were 59.1 (+/-18.1) years old, male:female =48:32, R:L=40:40. Fifty-six patients (70%) had previous unsuccessful retinal surgery, and 24 (30%) received heavy silicone oil at their first procedure. The extent of the detachments was 2.46 quadrants (+/-0.83) with macular involvement in 49 cases (61%). Fifty-six (67.5%) patients achieved retinal reattachment with one retinal operation and no tamponade, 64 (80%) achieved retinal reattachment with more than one operation and no tamponade, and 72 (90%) achieved a flat retina with tamponade in situ. Visual acuity rose from 1.48 LogMar (+/-0.91) to 1.12 (+/-0.82; p=0.009). Densiron was removed after 126 days (+/-55.1). The treatment of PVR remains challenging. No tamponade agent can provide simultaneous support for the superior as well as the inferior retina; therefore, a tamponade agent that "sinks" is a welcome new tool for the surgeon. We regard the use of heavy as well as conventional silicone oil as complementary to each other.</abstract><cop>Germany</cop><pmid>18636266</pmid><doi>10.1007/s00347-008-1798-8</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1433-0423
ispartof Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2009-04, Vol.106 (4), p.320-326
issn 1433-0423
language ger
recordid cdi_proquest_miscellaneous_67151381
source Alma/SFX Local Collection
subjects Female
Humans
Male
Middle Aged
Ophthalmic Solutions - administration & dosage
Recovery of Function - drug effects
Silicone Oils - administration & dosage
Treatment Outcome
Vision Disorders - diagnosis
Vision Disorders - etiology
Vision Disorders - prevention & control
Vitreoretinopathy, Proliferative - complications
Vitreoretinopathy, Proliferative - drug therapy
title Densiron-68 heavy silicone oil in cases of PVR. Anatomic and functional outcomes
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T20%3A48%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Densiron-68%20heavy%20silicone%20oil%20in%20cases%20of%20PVR.%20Anatomic%20and%20functional%20outcomes&rft.jtitle=Der%20Ophthalmologe%20:%20Zeitschrift%20der%20Deutschen%20Ophthalmologischen%20Gesellschaft&rft.au=Stappler,%20T&rft.date=2009-04&rft.volume=106&rft.issue=4&rft.spage=320&rft.epage=326&rft.pages=320-326&rft.eissn=1433-0423&rft_id=info:doi/10.1007/s00347-008-1798-8&rft_dat=%3Cproquest_pubme%3E67151381%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p139t-f985acac31729fb770b442c230030d9c000e836de81f664172e5dc7a28c391d93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67151381&rft_id=info:pmid/18636266&rfr_iscdi=true